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One of the key oncogenic pathways involved in melanoma aggressiveness, development and progression is the
RAS/BRAF/MEK pathway, whose alterations are found in most patients. These molecular anomalies are promising
targets for more effective anti-cancer therapies. Some Mek inhibitors showed promising antitumor activity, although
schedules and doses associated with low systemic toxicity need to be defined. In addition, it is now accepted that
cancers can arise from and be maintained by the cancer stem cells (CSC) or tumor-initiating cells (TIC), commonly
expanded in vitro as tumorspheres from several solid tumors, including melanoma (melanospheres). Here, we
investigated the potential targeting of MEK pathway by exploiting highly reliable in vitro and in vivo pre-clinical
models of melanomas based on melanospheres, as melanoma initiating cells (MIC) surrogates. MEK inhibition,
through PD0325901, provided a successful strategy to affect survival of mutated-BRAF melanospheres and growth
of wild type-BRAF melanospheres. A marked citotoxicity was observed in differentated melanoma cells regardless
BRAF mutational status. PD0325901 treatment, dramatically inhibited growth of melanosphere-generated xenografts
and determined impaired tumor vascularization of both mutated- and wild type-BRAF tumors, in the absence of
mice toxicity. These results suggest that MEK inhibition might represent a valid treatment option for patients with
both mutated- or wild type-BRAF melanomas, affecting tumor growth through multiple targets.
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Melanoma is one of the most aggressive cancers, with
increasing incidence worldwide [1,2]. Currently available
cytotoxic treatment options produce low rates of patient
response and have modest survival impact. Therefore,
there is an urgent need for development of more effective
therapies that may rely on molecularly targeted individualized
treatments. One of the key oncogenic pathways most
frequently altered in melanoma is the RAS/BRAF/MEK
pathway, thus providing potential promising therapeutic
targets [3-7]. Specific inhibitors have been developed,
partially investigated in vitro and some of them entered* Correspondence: adriana.eramo@iss.it
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reproduction in any medium, provided the orclinical trials [8-10]. Recent melanoma patient improvement
has been observed using targeted therapy or immunotherapy.
Indeed, the BRAF inhibitor, vemurafenib, and anti
cytotoxic T-lymphocyte antigen 4 (CTLA-4) antibody,
ipilimumab, demonstrated a survival benefit [11,12].
Despite the success of these treatments, most patients
eventually progress. In addition, BRAF regulatory loops
may circumvent its inhibition, thus Mek, being downstream
of BRAF in this key molecular pathway, may represent a
highly relevant clinical target [10,13,14]. Currently,
thirteen MEK inhibitors, including trametinib, pimasertib,
refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162),
RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973
(XL518), and AZD8330 have been tested clinically but
only trametinib (GSK1120212), a selective inhibitor of
MEK 1 and 2, has emerged as the first MEK inhibitor tod. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mutated melanoma. It is being evaluated by FDA for the
treatment of metastatic melanoma with BRAF V600
mutation. Finally, several clinical trials are currently ongoing
using MEK inhibitors in combination with chemotherapeu-
tic drugs (including dacarbazine or paclitaxel). However,
schedules and doses of Mek inhibitors compatible with
satisfactory antitumor efficacy associated with low systemic
toxicity need to be further defined [15-19]. On the other
hand, it would be relevant to determine whether the
pathway signature of the bulk tumor characterizes
also the melanoma initiating cell (MIC) compartment
in order to favor potentially more curative MIC-effective
molecularly targeted approaches [20-22]. In fact, increasing
experimental evidence supports the assertion that many
tumors including melanomas, contain Cancer Stem Cells
(CSC) or Tumor-Initiating Cells (TIC) and that they affect
tumor biology, thus acquiring dramatic clinical relevance
[4,20,23]. This course has triggered emerging interest and
important studies have been performed in the attempt to
understand the nature of MIC. Several putative MIC
markers have been identified including CD20, CD133,
ABCB5, CD271, JARIDB1, ALDH, however most of these
markers have not yet been validated in independent studies
[24-35]. Intense debate in this field is on-going and, to
date, several controversies surrounding this field remain
unsolved, including those concerning the frequency of
MIC. [29,30,35-38]. Extending beyond the general view
that CSC are static entities, recent evidence support a
model of dynamic stemness in which tumor maintenance,
in some solid tumors, may be a dynamic process mediated
by a temporarily distinct sub-population of cells that may
transiently acquire stemness properties and continually
arise and disappear (“moving target”) depending on the
tumor context, with consequent therapeutic implications
[30,32,37-39]. However, even though their frequency,
phenotype and nature still remain controversial issues, the
existence of a sub-population of cells with increased tumor-
initiating potential in melanomas is not questioned [40].
We investigated the activation and potential targeting
of the MEK pathway, exploiting highly reliable in vitro
and in vivo pre-clinical models of melanomas based on
melanospheres. We isolated the highly tumorigenic cell
sub-population from patient metastatic melanomas based on
its functional ability to grow indefinitely as melanospheres.
We previously proved that this approach efficiently enriches
tumorigenic cells in vitro [41-44]. Given that this strategy did
not rely on any prospective cell separation based on putative
CSC-markers, it allowed us to overcome the possible
bias of selecting cell populations based on the pres-
ence of transiently expressed antigens. The availability
of exponentially growing melanospheres allowed us to
obtain their deep in vitro validation and develop pre-




Tumor samples were obtained in accordance with consent
procedures approved by the Internal Review Board of
Sant’ Andrea Hospital, University ‘La Sapienza’, Rome,
Italy. All patients signed an informed consent form.
According to the Legislative Decree 116/92 which has
implemented in Italy the European Directive 86/609/EEC
on laboratory animal protection, the research protocol
“Analysis of effectiveness and tolerability of anti-tumor
therapeutic agents in mice carrying cancer stem cell-
derived tumors” (Principal Investigator Dr. Adriana Eramo)
has been approved by the Service for Biotechnology and
Animal Welfare of the Istituto Superiore di Sanità and
authorized by the Italian Ministry of Health (Decree
n° 217/2010-B). The animals used in the above mentioned
research protocol have been housed and treated according
to Legislative Decree 116/92 guidelines, and animal
welfare was routinely checked by veterinarians from
the Service for Biotechnology and Animal Welfare.
Isolation and culture of melanospheres and obtainment
of differentiated progeny
Tumor samples were obtained in accordance with
consent procedures approved by the Internal Review
Board of Department of Laboratory Medicine and
Pathology, S. Andrea Hospital, University La Sapienza,
Rome. Surgical specimens were dissociated and recovered
cells cultured in serum-free medium as previously described
[41,42]. Briefly, surgicalspecimens were washed several times
and left over night in DMEM:F-12 medium supplemented
with high doses of Penicillin/Streptomycin and Amphotericin
B in order to avoid contamination. Tissue dissociation was
carried out by enzymatic digestion (1.5 mg/ml collagenase II,
Gibco-Invitrogen, Carlsbad, CA and 20 μg DNAse I, Roche,
Mannheim, Germany) for 2 hours at 37°C. Recovered cells
were cultured in serum-free medium containing 50 μg/ml
insulin, 100 μg/ml apo-transferrin, 10 μg/ml putrescine,
0.03 μM sodium selenite, 2 μM progesterone, 0.6% glucose,
5 mM hepes, 0.1% sodium bicarbonate, 0.4% BSA, glutamine
and antibiotics, dissolved in DMEM-F12 medium
(Gibco-Invitrogen, Carlsbad, CA) and supplemented with
20 ng/ml EGF and 10 ng/ml bFGF. Flasks non-treated for
tissue culture were used in order to reduce cell adherence
and support growth as undifferentiated tumor-spheres.
Medium was replaced or supplemented with fresh growth
factors twice a week until cells started to grow forming
floating aggregates. Cultures were expanded by mechanical
partial dissociation of spheres, followed by re-plating of cells
and residual small aggregates in complete fresh medium.
In vitro differentiation was obtained by melanosphere
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East Rutherford, NJ, USA). Melanocytes (Lonza) were
cultured in the same conditions. Alternatively, differentiated
cells were obtained from standard (DMEM+10% FBS)
culture of tumor cells obtained from mouse xenografts.Immunohistochemistry on tumor sections
Immunohistochemistry was performed on formalin-fixed
paraffin-embedded or frozen tissue. Five μm paraffin
sections were dewaxed in xylene and rehydrated with
distilled water. Sections were treated with the heat-induced
epitope retrieval technique using a citrate buffer (pH6).
After peroxidase inhibition with 3% H2O2 for 20 minutes,
the slides were incubated with the following antibodies:
anti Phospho-p44/42 MAPK (Erk1/2) (Cell Signaling
Beverly, Ma, USA), anti MART-1, S100 and KI-67 (DAKO,
Glostrup, Denmark), anti CD34 (Rat monoclonal, clone
14.7, Novus Biologicals), anti-VEGF (rabbit polyclonal,
A20, Santa Cruz). The reaction was performed using Elite
Vector Stain ABC systems (Vector Laboratories) and
DAB chromogen substrate (DakoCytomation), followed
by counterstaining with haematoxylin.Chemotherapy and PD0325901 treatment
Three thousand cells obtained from melanosphere
dissociation were plated in 96-well flat-bottom plates.
Chemotherapeutic agents were added at the following
final concentrations: paclitaxel 30 ng/ml, cisplatin
5 μg/ml, dacarbazine 5 μg/ml and temozolomide 100 μM
and Mek inhibitor PD0325901 (Pfizer) 200nM. Cell
viability was evaluated after a 2 day treatment with
chemotherapic agents or a 3 day treatment with PD0325901
by both luminescent cell viability assays (CellTiter-Glo,
Promega, Madison, WI, USA) and cell count by trypan
blue exclusion. Data represented are means of three inde-
pendent experiments performed by the two experimental
procedures.Western blot
Proteins were resolved on 4-12% polyacrylamide gel
electrophoresis NuPAGE Bis-Tris (Invitrogen, Carlsbad, CA)
and transferred to nitrocellulose membranes. Rabbit
polyclonal anti-Phospho-S6 (Ser240/244) were purchased
from Cell Signaling (Beverly, Ma,USA), mouse mono-
clonal anti-Phospho-ERK (clone E-4) and anti-p16
(clone JC8), rabbit polyclonal anti-cyclin D1 (M20),
anti-VEGF (A20) and anti-Erk (K23) were purchased
from Santa Cruz (Santa Cruz, Ca, USA). β-Tubulin was
purchased from Sigma-Aldrich (St. Louis, Mo, USA). Anti-
mouse or anti-rabbit horseradish peroxidise-conjugated
secondary antibodies were purchased from Amersham
Pharmacia Biotech (Buckinghamshire, UK).Inhibitors screening
Eighty inhibitors targeting different survival pathways (Enzo
Life Sciences, New York, NY, http://www.enzolifesciences.
com) were tested on 3 different melanospheres samples, at
the final concentration of 5 μM. Cell viability was evaluated
after 2 days of treatment by luminescent cell viability assay
(CellTiter-Glo, Promega, Madison, WI, USA).Cell cycle analysis and apoptosis assay
For cell cycle assay 1 × 105 cells were washed with PBS
and suspended in Nicoletti buffer (0.1% sodium citrate,
pH 7.4/0.1% Triton X) containing 100 μg/ml propidium
iodide and 200 μg/ml RNaseA. After 2 hrs of incuba-
tion at 4°C, samples were analyzed with FACS Canto
(Becton Dickinson, Franklin Lake, NJ, USA).
Apoptosis was measured using the Apoptosis Detection
Kit I (BD Bioscience). One million cells/ml were stained
with 5 μl of Annexin V-FITC (BD PharMingen) and
10 μg/ml 7AAD (Sigma-Aldrich, St. Louis, Mo, USA) in a
total volume of 100 μl and analyzed by FACS Canto.Xenograft generation and mice treatment
The research protocol “Analysis of effectiveness and toler-
ability of anti-tumor therapeutic agents in mice carrying
cancer stem cell-derived tumors” (P.I. Dr. Adriana Eramo)
has been approved by the Service for Biotechnology and
Animal Welfare of the Istituto Superiore di Sanità and
authorized by the Italian Ministry of Health (Decree
n° 217/2010-B).
Melanospheres were injected in complete medium:
Matrigel (BD Pharmingen) in the flank of four to six
week-old female NOD-SCID or nude mice (Charles River).
Once tumor diameters reached a maximum of 10 mm,
mice were sacrificed, tumor tissues collected, fixed in
buffered formalin and analyzed by immunohistochemistry.
For drug experiments, when tumors reached a mean of
0.5 cm in diameter, mice were randomized into 3 groups.
One group was left untreated and the others were treated
for 3 weeks with 12.5 mg/Kg or 25 mg/Kg of PD0325901
(freshly dissolved in 0.5% hydrossimethylcellulose/0.2%
tween80) administered orally by gavage on day 1 and day
4 of each week. Tumors were measured twice a week for
the 3 weeks using a caliper, and mice were monitored for
signs of drug-induced toxicity and weighed with similar
schedules. At the end of treatment tumors werefixed in
formalin and embedded in paraffin for IHC or frozen
at −80°C for protein lysates. Protein lysates were obtained
homogenizing three times at high speed (Polytron
model 200, Pro Scientific Inc.) at 4°C for 20 minutes
in a homogenizing solution containing 10 mM Tris pH 8.0,
150 mM NaCl, 1 mM EDTA, 1 mM orthovanadate, 1%
Triton X-100, and 60 mM N-octyl-b-D-glucopyranoside,
in the presence of protease inhibitors. After 10 min of
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was determined by the Bradford assay (Biorad).
Statistical analysis
Results are expressed as means ± S.D: Statistical calculations
were performed with Microsoft Excel analysis tools.
Comparisons between means were performed by Student’s
t test, and the P < 0.05 was regarded as significant.
Results
Melanospheres isolated from metastatic melanoma
tumors possess stem cell properties, are highly
tumorigenic in vivo and recapitulate the patient tumor
Ten patient-derived metastatic melanoma specimens
were enzymatically dissociated and tumor cells were cultured
in selective conditions for CSC (tumor spheres), as previously
described [41-44]. Following prolonged culture, we obtained
exponentially growing “melanospheres” with efficiency of
80% (Figure 1A left). The same cells cultured in conditions
specific for the growth of melanocytes generated monolayers
of tumor cells whose morphology resembled differen-
tiated cells, suggesting the capacity of melanospheres
to differentiate in vitro (Figure 1A right).
We next investigated the expression of antigens that
have been previously associated with MIC. Melanospheres
did not express CD133, CD20, CD24, ABCB5 or CD271
(Additional file 1: Figure S1A-B), while p-glycoprotein was
detectable at low levels. They expressed stem cell-related
markers as c-Kit, Cripto, CD146, CD44 and CD166
(Additional file 1: Figure S1A) in agreement with previous
reports on cell line-derived melanospheres [38]. Finally,
embryonic stem cell markers Nanog and Oct-4 were
detected at the RNA level in all samples analyzed
(Additional file 1: Figure S1C). The CD44 isoform V6
was specifically restricted to melanospheres, being not
expressed in differentiated cells, nor in tumor cells
freshly isolated from melanosphere-derived xenografts
nor in melanocytes (Additional file 1: Figure S1D).
Melanospheres could be expanded in vitro for several
months and their proliferation rate was not lost with
time (Additional file 2: Figure S2A). They were composed
by a large (mean 42% ± 8 in all examined samples) fraction
of self-renewing sphere-reforming cells (Additional file 2:
Figure S2B upper left). Finally, secondary and tertiary
spheres were formed with a similar frequency and tertiary
spheres were able to proliferate indefinitely, indicating that
the fraction of self-renewing cells did not decrease with
passages (Additional file 2: Figure S2B upper right panel).
The clonogenic activity was higher in melanospheres
than in their differentiated counterpart (Additional file 2:
Figure S2B lower panels). Under appropriate conditions,
melanospheres generated a progeny of cells with morph-
ology and phenotype of melanocytic, adipogenic or
osteogenic cells, demonstrating multiple differentiation abilityand recapitulating the plasticity of neural crest cells
(Additional file 2:Figure S2C).
Melanospheres were highly tumorigenic when injected
subcutaneously in NOD Scid or Nude mice and all
samples displayed tumor take of 100% down to 25000
cells. For one sample we performed a limiting dilution
experiment and even as low as 5 cells readily generated
a tumor within 8 weeks (Figure 1B and C). In contrast,
melanosphere-derived differentiated cells displayed a
decreased and delayed tumor growth in vivo, and as many
as 5x104 differentiated cells generated a slowly growing
tumor with a 10-week delay post-injection (Figure 1B).
Immunohistochemical analysis of melanosphere-derived
xenografts, performed for all samples, revealed a high
similarity between the xenograft and the original patient
tumor in terms of morphology and expression of the
melanoma-associated diagnostic antigens MART1 and
S100 (Figure 1D is a representative image). Following
xenograft dissociation and re-injection we easily obtained
secondary and tertiary tumors, suggesting that tumorigenic
potential was not lost with passages in mice, in fact these
results proved the ability of tumorigenic cells to self-renew
in vivo (results not shown). Based on these in vitro
and in vivo results, we considered melanospheres as
surrogate of melanoma-initiating cells (MIC) exploitable
for pre-clinical experimentation.
Melanospheres are resistant to chemotherapeutic drugs
and to most pathway inhibitors
We investigated the response of melaospheres to
chemotherapeutic agents currently used in the treatment
of melanoma patients. Melanospheres were exposed to
cisplatin, temozolomide, dacarbazine and paclitaxel for
48 hours and cell viability was assessed by MTT assay.
Overall a weak cytotoxic effect (<40% in all samples and
with all drugs) was observed with no therapeutic win-
dow as compared to normal melanocytes (Figure 2A).
Conversely, differentiated cells were extremely sensitive to
cisplatin, in 3 out of 3 samples assessed (Figure 2B is a
representative sample).
We next investigated the cytotoxic potential of a panel
of 80 signaling pathway inhibitors on melanospheres
derived from patient #1 and #2 and #3 encompassing in-
hibitors of RAS/RAF/MEK and PI3K/AKT pathways as
well as tyrosine kinase receptors. Only inhibitors of
the RAS/RAF/MEK pathway (including the MEK in-
hibitors PD098059 and U0126 and the Erk2 inhibitor
5-iodotubercidin) showed promising antitumor activity
in terms of reduced cell viability, as measured by MTTassay.
The other drugs, except for the broadly toxic compound
staurosporin used as positive control, were nearly
unable to reduce cell viability/proliferation, although
all compounds were used at doses higher than the
described IC50 in order to enhance their activity. A
Figure 1 (See legend on next page.)
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Figure 1 Melanosphere isolation and validation. A) Image of melanospheres (left) and their differentiated progeny (right). B) Tumor volumes
of xenografts generated by spheres or differentiated (diff) melanoma cells injected subcutaneously in Nude mice at the indicated cell doses.
Mean ± SD of 3 independent experiments is shown. ** p < 0,01. C) Table of melanospheres tumorigenicity in dose response experiments. Cell
numbers, number of mice injected and percentage of tumor engraftment is indicated for each condition. Tumors were monitored for 8 weeks
post-injection. D) Hematoxylin and eosin (H&E) or immunohistochemistry for the indicated antigens performed on patient tumor or xenograft
generated by melanospheres. The original magnification of each image is indicated.
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samples (Figure 2C shows a representative one). In
line with the melanosphere sensitivity to compounds
targeting the MAPK pathways, we observed the activation
of this signaling pathway with high levels of phosphorylation
of Erk and downstream S6 (Figure 2D). We also found high
levels of Cyclin-D and undetectable p16 (Figure 2D). These
results are in agreement with the frequent alteration of the
RAS/RAF/MEK pathway and cell cycle deregulation found
in melanomas. Next, we analyzed DNA sequences of genes
whose alterations may contribute to the abnormal pathway
activation. As reported in the Additional file 3: Table S1,
NRAS was never mutated in the analyzed samples. Instead,
despite the ubiquitous Erk phosphorylation found in
melanospheres, the BRAF-V600E mutation was detected
in samples 1, 2 and 4, BRAF-V600K mutation was found
in samples 5 and 8, while samples 3, 6 and 7 displayed
wild type BRAF. All samples displayed wild type PTEN.
Finally, sequence analysis of the exon 4 and 5 of GNAQ
gene, whose mutations have been associated with wild
type BRAF and NRAS melanomas, revealed wild type
status in all samples (Additional file 3: Table S1 and
Additional file 4) [45].
Treatment with MEK inhibitor PD0325901 results in
strong antitumor activity against melanospheres
The encouraging activity of the MEK inhibitors used in the
pathway inhibitor screening (see above) prompted us to
study the antitumor effect of the MEK inhibitor PD0325901
on the melanospheres, based on its antitumor activity
described in clinical studies [16]. Following 3 day-exposure
to PD0325901, at doses comparable with those achieved
in vivo, both wild type and mutated-BRAF cells displayed
decreased proliferation/viability, with mutated-BRAF
samples being more sensitive to the drug (Figure 3A).
In order to distinguish the cytostatic from the cytotoxic effect
and to unravel the molecular mechanisms of PD0325901
antitumor activity against malenospheres, we first performed
cell cycle analysis of control and treated samples. After short
exposure (2 days), PD0325901 greatly affected cell cycle
progression by determining accumulation of cells in the G1
phase, both in the wild type and mutated-BRAF samples
(Figure 3B). At the molecular level, together with a striking
decrease in Cyclin D levels which is in line with the observed
cell cycle arrest, treated samples displayed a decline in Erkand S6 phosphorylation, thus, proving MEK signaling
inhibition by PD0325901 (Figure 3C). Given that PD0325901
may induce apoptosis in melanoma cell lines, we investigated
whether a similar mechanism could account for the reduced
number of viable cells in PD0325901-treated melanosphere
samples [17]. Indeed, PD0325901-treated mutant-BRAF
melanospheres contained a high fraction of apoptotic
annexin V-positive cells compared to control samples. In
contrast, PD0325901 treated wild type-BRAF melanospheres
did not show such a dramatic increase (Figure 3D).
Importantly, we found that both wild type and mutated-
BRAF melanoma differentiated cells, were exquisitely
sensitive to the drug, as indicated by the high fraction of
sub-diploid cells detected in treated samples stained with
Propidium Iodide (Figure 3E). This additional apoptosis
assay confirmed that, at the level of melanospheres,
only mutated-BRAF cells rapidly underwent PD0325901-
induced apoptosis, while apoptotic hypodiploid DNA-cells
were almost absent in the treated wild type-BRAF
cells (Figure 3E). These results indicate that PD0325901
exerted strong cytotoxic activity against mutant-BRAF
melanospheres, and a strong cytostatic activity against
wild type-BRAF melanospheres, where cytotoxicity played
a minor role. In contrast, differentiated melanoma cells
were efficiently killed by PD0325901, regardless BRAF
status (Figure 3E).
Treatment with MEK inhibitor PD0325901 results in strong
antitumor activity in melanosphere-derived xenografts
We investigated the activity of PD0325901 against
melanosphere-generated subcutaneous xenografts. Doses
of 25 or 12.5 mg/Kg were investigated in order to define
a well tolerated dose with reduced toxicity and maximum
antitumor activity, as the optimal doses and schedules for
antitumor activity in the absence of toxicity was not
previously determined in cancer patients. We chose
the bi-weekly treatment schedule for drug administration
based on previously published results showing high
systemic toxicity occurring during daily drug administration
[46] and as we previously experienced similar results in
mice (results not shown). PD0325901 administration, by
oral gavage, caused a striking reduction in tumor growth at
both drug doses, displaying stronger activity for the
higher dose (Figure 4A and Additional file 5: Figure S3A).
Importantly, treated mice did not exhibit signs of toxicity
Figure 2 Drug resistance of melanosphere and pathway activation. A) Cell viability of undifferentiated melanospheres of the indicated
samples and melanocytes treated with the indicated drugs. Mean ± SD of 3 independent experiments is shown. ** p < 0,01. B) Cell viability of
melanospheres (undifferentiated) and their progeny (differentiated) exposed to the indicated chemotherapeutic agents. A representative sample
is shown. Mean ± SD of 3 independent experiments is shown. *** p < 0,001. C) Cell viability of melanospheres exposed to the indicated kinase
inhibitors. Mean ± SD of 3 independent experiments is shown. ** p < 0,01; * p < 0,05 D) Immunoblot analysis of the indicated proteins or
phosphoproteins in melanospheres. U251 and T98G glioblastoma cell lines were used as p-ERK positive and negative control, respectively.
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xenografts displayed markedly reduced levels of Erk and
downstream S6 phosphorylation in treated tumors,
indicating that PD0325901 levels reached in vivo were
sufficient to achieve almost complete Erk inactivation
and that the effects observed on tumors were caused
by specific PD0325901 activity (Additional file 5: Figure S3B).Immunohistochemistry analysis of xenografts revealed
decreased proliferation rates for treated tumors (lower
Ki-67 expression in comparison with control tumors) and
reduced activation of the Mek/Erk pathway (lower Erk
phosphorylation) (Figure 4B). In addition, staining with
murine CD34 antibody demonstrated a strong inhibitory
effect of PD0325901 on tumor vascularization, as control
Figure 3 Antitumor activity of PD0325901 on melanospheres and their progeny. A) Cell viability (Cell Titer Glo assay, Promega) of
melanospheres with mutated- or wild type-BRAF treated with the indicated drug doses. Mean ± SD of 3 independent experiments is shown.
*** p < 0,001. Cell cycle distribution (B) and immunoblot analysis of pathway activation (C) of melanospheres after a 2 day drug exposure.
D) Percentage of AnnexinV positive cells in control or PD0325901-treated representative melanospheres samples with mutated- or wild type-BRAF.
Mean ± SD of 3 independent experiments is shown. ** p < 0,01. E) Propidium Iodide staining and flow cytometric analysis of representative samples of
melanospheres (stem) or differentiated (diff) melanoma cells with mutated- or wild type-BRAF untreated or exposed to PD0325901. The percentage of
apoptotic cells with subdiployd DNA is indicated for each condition and cell type. Standard deviations of the percentages are indicated for each
condition. **≤ 0,01, ***≤ 0,001 compared to untreated controls.
Sette et al. Journal of Experimental & Clinical Cancer Research 2013, 32:91 Page 8 of 13
http://www.jeccr.com/content/32/1/91tumors contained large vessels, while treated tumors
displayed drastically compromised vasculature composed
by minuscule vessels (Figure 4B). A decrease of tumor
vascularization appeared also by macroscopic observation
of the tumors (Additional file 5: Figure S3A). Importantly,
similar results were obtained when xenografts were
generated by wild type-BRAF melanospheres indicating
that this strategy might constitute a potentially exploitable
therapeutic approach both for mutated-BRAF and wild
type-BRAF melanoma patients (Figure 4C and D).
Immunoblot analysis showed that VEGF levels were lower
in treated-melanospheres (Figure 4E) and immunohisto-
chemistry analysis showed that PD0325901-treated
xenografts expressed reduced levels of VEGF in comparison
with control tumors (Figure 4F). These results were
obtained both for mutated BRAF and wild type BRAF
melanospheres and xenografts and suggest that Mek
inhibition might determine, together with a direct
cytotoxic/cytostatic effect on tumor cells, a reduction
of the tumor cell-dependent pro-angiogenic activity
in vivo.Discussion
In the last years, several controversial findings concerning
MIC has lead to intense investigation aiming at identifying
and understanding the phenotype, frequency and behavior
of these cells. Lately, a novel concept has emerged that
partially modified the hierarchical organization model of
tumors maintained by CSC, at least for some tumors,
including melanoma. In contrast to the static and
irreversible properties of CSC, this model proposes the
existence of dynamic CSC that may arise from non
stem tumor cells and possibly disappear upon micro-
environmental stimuli [32,39]. Consequently, these CSC
may display temporary changing phenotype and properties.
This concept may partially explain the contradictory
results that continue to emerge concerning MIC markers,
frequency and tumorigenicity [40]. In fact, the identification
of MIC based on marker expression has failed, so far,
as suggested by the scarce agreement between different
reports. Therefore, we used an alternative more reliable
method for the isolation of tumorigenic melanoma cells
relying on functional rather than phenotypic features
Figure 4 (See legend on next page.)
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Figure 4 Antitumor activity of PD in melanosphere-derived subcutaneous xenografts. Growth curves of xenografts derived from
mutant-BRAF (A) or wild type-BRAF (C) melanospheres in control or PD0325901-treated mice. Mean ± SD of 3 independent experiments is shown.
*** p < 0,001. B-D) Immunohistochemistry for KI-67, p-Erk and mouse CD34 in control or treated BRAF-mutated (B) or BRAF-wild type (D) xenografts.
E) Immunoblot for VEGF expression in control or PD0325901-treated representative melanospheres with mutated- or wild type-BRAF.
F) Immunohistochemistry for VEGF in control or PD0325901-treated xenografts.
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grow as spheroid/aggregates, named tumor “spheres” in
stem cell suitable culture conditions. This methodology
provides cultures that are enriched in tumorigenic cells
with CSC properties as we previously demonstrated for
other tumors [41-44]. Highly tumorigenic cell-enriched
populations were obtained without any prospective cell
selection based on putative CSC-markers. This was done
in order to circumvent the biased selection of cells relying
on antigens endowed with weak CSC function or possibly
undergoing dynamic temporal changes, as mentioned
above. This system provided virtually unlimited amounts
of highly tumorigenic cells from patient tumors that,
besides carrying out a thorough investigation on their
phenotype, nature, in vitro and in vivo properties
necessary to accurately validate the experimental strategy,
it allowed to investigate potential mechanisms of
chemoresistance and potential strategies to overcome
their aggressiveness through the inhibition of activated
survival pathways. In agreement with other reports, we
found little consensus with marker expression that was
previously associated with putative MIC identified in
different experimental conditions [38]. More importantly,
all in vitro and in vivo functional assays supported
the high stemness potential of melanospheres expanded
in vitro (high proliferation, self renewal and multidifferen-
tiative potentials, high tumorigenicity and ability to mimic
the patient tumor in mice). They were highly chemoresis-
tant even toward chemotherapeutic agents that were
cytotoxic against differentiated cells and displayed a
highly activated MAPK pathway, regardless of the
BRAF mutational status. Thus, we used these highly
valuable in vitro and in vivo models to investigate the
possibility to counteract melanoma aggressiveness by
targeting the oncogenic MAPK pathway in these cells.
Inhibition of Ras/RAF/MEK pathway, through the MEK
inhibitor PD0325901, determined a stronger cytotoxic
effect against mutant-BRAF melanospheres, while wild
type-BRAF melanospheres mainly underwent growth
inhibition upon MEK blockade. On the contrary, differen-
tiated melanoma cells were exquisitely sensitive to MEK
inhibition regardless BRAF status, undergoing massive
apoptosis upon treatment. PD0325901 determined a strong
antitumor efficacy in melanosphere-derived xenografts
both with wild type or mutated BRAF. It is likely that the
prompt and dramatic antitumor activity of MEK inhibition
observed in vivo, both against mutated and wild typeBRAF xenografts, might depend on the strong cytotoxicity
of the drug against differentiated cells of both types. In
addition, MEK inhibition determined a decreased VEGF
production by melanospheres in vitro and a markedly
reduced vascularization of tumors. This suggests that the
antitumor effect of the drug in vivo may derive from both
its direct toxicity on tumor cells and from a decreased
production of the pro-angiogenic factor VEGF by tumor
cells, hampering the production of tumor blood vessels. In
line with these results, previous studies have shown that
reduced VEGF expression was associated with inhibition
of melanoma growth in mice [47].
Our results showed that PD0325901 antitumor activity
was observed in both stem and non-stem cell populations,
thus the proposed approach may represent a potentially
successful therapeutic strategy against melanoma from
both a classical hierarchical static model of CSC point of
view and from a dynamic stemness perspective [48]. In
fact, based on the recently proposed model of dynamic
tumorigenic cells uncovering their ability to appear and
disappear in different circumstances, it is clear that only a
strategy that targets the stem and differentiated cells
simultaneously may represent a potential tumor eradicating
therapy. In fact, in this view, both stem and differentiated
tumor cells need to be simultaneously depleted in
order to avoid reappearance of the tumorigenic cells after
interrupting stem cell-specific cytotoxic treatment [49,50].
Finally, a recent clinical trial reported evidence of
PD0325901 systemic toxicity in treated patients [51].
Indeed, we observed toxicity in mice when followed a
similar daily drug administration of high doses of MEK
inhibitor (results not shown). In contrast, the twice a
week low dose regimen did not cause toxicity in mice,
while drastically affecting tumor growth, thus, indicating
that optimization of the treatment schedule could lead
to very promising results in patients. Notably, a recent
phase III trial showed that treatment with a new MEK
inhibitor (GSK1120212, GlaxoSmithKline) determined
improved rates of progression-free and overall survival
among patients who had metastatic melanoma with
mutated BRAF, with very low toxicity [46]. In line with
these clinical reports, we obtained significant activity
when this drug was used against both tumorigenic and dif-
ferentiated melanoma cells (Additional file 6: Figure S4).
Importantly, we found that Mek inhibition in vivo
determined a dramatic antitumor activity both in mutated-
and wild type-BRAF tumors, suggesting that MEK
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and safe strategy to counteract melanoma growth, thus
improving patient outcome. However, considering the
merely cytostatic activity exerted by MEK inhibitor against
wild type BRAF melanoma stem-like cells in vitro, it may
be possible that MEK inhibition might kill only the
differentiated cells in vivo, as well, with consequent
enrichemnt of tumors in stem-like cells. On the other
hand, we found that tumors displayed reduced angiogenesis
when treated with the drug, indicating an additional
antitumor mechanism exerted by MEK inhibitor, besides the
direct toxicity on tumor cells. Vasculature was dramatically
compromised, with similar extent, in mutated and wild type
BRAF xenografts, and most likely this event contributed to
determine the dramatic inhibition of tumor growth observed
in treated xenografts of both types. These results suggest that
the marked antitumor activity of MEK inhibition may be
mediated by multiple mechanisms in vivo, the direct cyto-
toxic or cytostatic activity against stem-like and differentiated
tumor cells and the anti-angiogenic activity resulting from
reduced tumor cell production of VEGF. The relative contri-
bution of these two mechanisms might determine whether
melanoma stem-like cells of wild type BRAF tumors are
killed or spared by the treatment. Nevertheless, it may be
possible that aggressiveness of both mutated and wild type
tumors may increase following MEK inhibition, indicating an
enrichment of treatment-resistant stem-like cells, similarly to
what may occur during chemotherapy [52,53]. Even in this
case, the possible enrichment of tumorigenic cells might be
more limited in MEK-treated tumors in comparison with
chemotherapy-treated tumors, as it might be counteracted
by the anti angiogenic effect determined by Mek inhibition.
Finally, as MEK inhibition was highly cytotoxic for
differentiated melanoma cells it is likely to hypothesize a
combined treatment for wild type BRAF tumors with
MEK inhibitors in association with differentiating agents.
Hypothetically, this combination might lead to the
exhaustion of stem-like cells that upon forced differenti-
ation can be efficiently killed by the MEK inhibitor, with
potential long term benefit for melanoma patients.
Conclusions
The data presented in this study demonstrated that
MEK inhibition determines a strong antitumor activity
against the more tumorigenic metastatic melanoma
cells expanded in vitro as melanospheres and against
melanospheres-generated xenografts both with mutated
or wild type BRAF. Although further studies are needed
to clarify the long term effects of this approach, our find-
ings suggest that, MEK inhibition, due to its multitargeting
effect in vivo, might represent a therapeutic strategy with
efficacy against the tumor-maintaining cells in metastatic
melanoma, with potential relevance even in patients
lacking BRAF mutation.Additional files
Additional file 1: Figure S1. Phenotypic characterization of
melanospheres. A) Flow cytometric analysis of melanospheres for the
indicated stem cell-associated antigens. White histograms are negative
controls, grey histograms are specific antibody stainings. B) RT-PCR analysis
for the expression of ABCB-5 in the following samples: (M) marker,
melanospheres sample 1 to 5, melanocytes, positive control
(lung cancer stem cells), negative control. C) RT-PCR analysis for the expression
of Nanog and Oct-4 in the samples indicated as in B. D) Flow cytometric
analysis of CD44 variant 6 in melanospheres, differentiated cells, fresh
xenografts and melanocytes as indicated. Each type of cells was
stained with unspecific antibody as negative control in the upper
panels (control).
Additional file 2: Figure S2. In vitro stem cell properties of melanospheres.
A) Proliferative potential of melanospheres. Growth curve of melanospheres at
early passages (kept in culture for few weeks after the isolation and before
the experiment) or at late passages (after 6 month-culture). Cells were
counted each week by trypan blue exclusion. B) Self renewing ability
(percentage of clonogenic cells) of melanospheres. Percentage of cells able to
form new spheres after single cell plating in limiting dilution analysis for the
indicated samples (first panel). Percentage of self-renewing cells obtained
from primary, secondary or tertiary spheres in limiting dilution analysis
(second panel). Percentage of self renewing in undifferentiated (spheres)
or differentiated cells obtained under stem cell culture conditions
(undifferentiative) or under differentiative conditions as indicated (third panel).
Comparison of self-renewing cells in cells previously expanded under stem
cell conditions (SC medium) or under standard conditions for differentiated
melanoma cells (RPMI) (last panel). The values represent mean +/- SD of three
independent experiments. Student’ s T test was used to determine p-value
(*p<0,1; **p<0,01; ***p<0,001). C) Multidifferentiation potential of melanospheres.
(left) Melanogenic differentiation (S-100); (middle) Adipogenic
differentiation (Oil-red-O); (right) Osteogenic differentiation
(Alcaline Phosphatase activity).
Additional file 3: Table S1. Clinical Staging of melanomas and analysis of
genetic status of the NRAS, BRAF, PTEN and GNAQ genes in melanospheres.
Additional file 4: Analysis of genetic status of the NRAS, BRAF,
PTEN and GNAQ genes in melanospheres.
Additional file 5: Figure S3. Antitumor activity of PD in
melanosphere-derived subcutaneous xenografts. Tumor images (A) and
immunoblot for pathway activation (B) of melanosphere-derived xenografts
obtained from control or PD0325901-treated mice.
Additional file 6: Figure S4. Mek inhibition by GSK1120212. A) Three
thousand cells obtained from melanosphere dissociation were plated in
96-well flat-bottom plates and Mek inhibitor GSK1120212 (Glaxo Smith Kline)
was added at the indicated doses. Cell viability was evaluated after 3 days
treatment by luminescent cell viability assay (CellTiter-Glo, Promega, Madison,
WI, USA). B) Stem versus differentiated melanoma cells (as indicated) were
treated as in A for comparison of Mek inhibitor activity against the different
cell types. Data represented are mean of three independent experiments
performed with the two experimental procedures. Student’ s T test was used
to determine p-value (**p<0,01; ***p<0,001).Competing interests
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